Replimune Group Files 8-K

Ticker: REPL · Form: 8-K · Filed: 2025-07-22T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure, regulation-fd

TL;DR

Replimune Group filed an 8-K on 7/22, reporting events from 7/21. Check for updates.

AI Summary

Replimune Group, Inc. filed an 8-K on July 22, 2025, reporting on events that occurred on July 21, 2025. The filing indicates disclosures related to Regulation FD, other events, and financial statements and exhibits. The company, incorporated in Delaware, is based in Woburn, MA, and operates in the biological products sector.

Why It Matters

This 8-K filing signals that Replimune Group, Inc. has made important disclosures to the SEC, potentially impacting investors' understanding of the company's current status and future outlook.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting various events and disclosures, not indicating any immediate or significant negative developments.

Key Players & Entities

FAQ

What specific events are being disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text.

What are the 'Other Events' being reported by Replimune Group, Inc.?

The filing lists 'Other Events' as an item, but the nature of these events is not detailed in the provided text.

What financial statements and exhibits are included in this filing?

The filing mentions 'Financial Statements and Exhibits' as an item, but the specific content of these documents is not detailed in the provided text.

When was Replimune Group, Inc. incorporated and what is its fiscal year end?

Replimune Group, Inc. was incorporated in Delaware and its fiscal year ends on March 31.

What is the business address and phone number for Replimune Group, Inc.?

The business address is 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801, and the telephone number is (781) 222-9600.

From the Filing

0001104659-25-069489.txt : 20250722 0001104659-25-069489.hdr.sgml : 20250722 20250722081847 ACCESSION NUMBER: 0001104659-25-069489 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250721 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250722 DATE AS OF CHANGE: 20250722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 251138736 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 tm2521403d1_8k.htm FORM 8-K false 0001737953 0001737953 2025-07-21 2025-07-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  July 21, 2025       REPLIMUNE GROUP, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38596   82-2082553 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number)   500 Unicorn Park Drive Suite 303 Woburn , MA 01801 (Address of principal executive offices, including Zip Code)   Registrant’s telephone number, including area code: ( 781 ) 222-9600   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:     ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   REPL   The Nasdaq Stock Market LLC (Nasdaq Global Select Market)   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨               Item 7.01 Regulation FD Disclosure .   On July 22, 2025, Replimune Group, Inc. (the “Company”) issued a news release announcing that the U.S. Food and Drug Administration (the “FDA”) has issued a Complete Response Letter regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. A copy of such news release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.   In accordance with General Instructio

View on Read The Filing